Scientists have long known that some viruses and bacteria begin infections by latching first onto sugar molecules on the surfaces of cells lining the sinuses and throat of mammals, including humans. Viral particles, for instance, can attach to these molecules, called sialic acids, or SAs, like keys fitting into locks.

Now, a new study in infant mice shows that keeping virus particles from attaching to SAs limits more than just the entry of influenza A viral infections, but also hinders their exit (shedding) and transmission from mouse to mouse. Such infections are the main cause of the seasonal flu, which kills more than 36,000 Americans annually. While vaccines to guard against infection and symptom treatments exist, they are not foolproof, scientists say, and more strategies are needed to prevent infection from spreading.

Led by researchers from NYU Grossman School of Medicine, the study team stripped away, or desialylated, SA receptors by placing directly into mouse nasal cavities a neuraminidase enzyme known to loosen the acids’ ability to remain attached to cell surfaces. The infant mice were then infected with influenza A. Results showed treatment with the neuraminidase enzyme dramatically cut mouse-to-mouse transmission rates by at least half: in the half-dozen influenza strains tested, this reduction ranged from 51 to 100 percent.

Published in the American Society for Microbiology journal mBio online January 11, the work was conducted in infant mice, which unlike adult mice or those even a few months older, were found by the research team to have many sialic acids in the upper portion of their respiratory tract. Specifically, the team blocked two SAs, technically called alpha-2,3 SA and alpha-2,6 SA receptors (the locks). These are known to be widely present in the human respiratory tract, and researchers say this makes infant mice a strong comparable model for studying the spread of the infectious disease in children, who are recognized as important drivers of flu transmission among people.

“If further experiments in humans prove successful, desialylating neuraminidase enzymes may prevent the flu from spreading,” said lead study investigator and infectious disease specialist Mila B. Ortigoza, MD, PhD.

“While current approaches with vaccines and treatments target the virus, ours is the first study to demonstrate that treating the host, either infected mice or potentially infected humans, to prevent them from transmitting the virus to another host could be another effective strategy for combating pervasive infectious diseases,” said Dr. Ortigoza, who is also an assistant professor in the Departments of Medicine and Microbiology at NYU Langone.

Dr. Ortigoza cautions that extensive clinical research is needed before neuraminidases can be considered for approval as a treatment in humans. She says the team already has plans for more experiments to examine why infants are more susceptible to infection from respiratory viruses and whether blocking sialic acids in children can also prevent the spread of influenza.

Funding support for this study was provided by National Institutes of Health grants P30CA016087, S10OD021747, K08AI141759, and R01AI150893. Ansun Biopharma of San Diego provided the experimental neuraminidase drug used in these experiments but was otherwise not involved in the study.

In addition to Dr. Ortigoza, other NYU Langone researchers involved in this study are Catherina Mobini; Hedy Rocha; Stacey Bartlett, PhD; Cynthia A. Loomis, MD, PhD; and Jeffrey N. Weiser, MD. Dr. Weiser is the Jan T. Vilcek Professor of Molecular Pathogenesis in the Department of Microbiology at NYU Langone and chair of the department.

Media Inquiries

David March
Phone: 212-404-3528
David.March@NYULangone.org